Navigation Links
Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Date:1/4/2012

BLUE BELL, Pa., Jan. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that it has promoted Niranjan Y. Sardesai, Ph.D., from Senior Vice President Research and Development to Chief Operating Officer. In his expanded role, Dr. Sardesai will be responsible for corporate and business development for the company in addition to continuing to oversee research and development. Inovio also announced the retirement of Kevin W. Rassas, former Senior Vice President Business Development.

Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, said, "Niranjan brings to the COO position a strong combination of strategic business, transactional, and technical skills and broad operating experience. He has overseen the integration, development, and growth of Inovio's pipeline through the advancement of its proprietary technology as well as licensing and M&A efforts. We are pleased to have him assume this broader responsibility to help guide and execute Inovio's business plan to develop important new vaccines. Kevin played a vital role in the formative years of our predecessor company, VGX Pharmaceuticals, bringing big Pharma management experience to an entrepreneurial environment, and subsequently in advancing Inovio's key business relationships. We thank him for his contribution and commitment to Inovio and wish him the very best in the future."

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. Dr. Sardesai is responsible for leading the company's product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He has secured ov
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
2. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
3. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
4. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
5. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
6. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... OMAHA, Neb., April 1, 2011 Transgenomic, ... scientists have completed studies employing the company,s high-sensitivity ... COLD-PCR and BLOCker™-Sequencing.  Results from these studies will ... Research (AACR) meeting in Orlando, Florida, April 2-6, ...
... National Institute of Standards and Technology (NIST) have developed a ... probes used to study nanoscale structures in situ and as ... improve the accuracy of the most precise and delicate nanoscale ... trying to measure the contours of a surface with a ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT ) ... distributor of probiotics products in China, today announced that ... its newly signed U.S. customer. The U.S. ... and formally entered into its agreement with China-Biotics on ...
Cached Biology Technology:Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Getting the point: Real-time monitoring of atomic-microscope probes adjusts for wear 2China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3
(Date:4/23/2014)... in French and German . ... humans and other mammals, the difference between sexes depends on one ... only in males, where the two sexual chromosomes are X and ... ultimately responsible for all the morphological and physiological differences between males ... A very long time ago, the X and Y were identical, ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... (4/23/14) -- Researchers have found evidence of an ... that increase aggressive behavior in children, especially in ... all children exposed to prenatal smoking will have ... not," said Brian Boutwell, Assistant Professor at Sam ... senior author on the study. "One possible ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3Picky male black widow spiders prefer well-fed virgins 2Genetics risk, prenatal smoking may predict behavioral problems 2
... Clonorchis sinensis affects more than 35 million people ... by this parasite causes clonorchiasis. Repeated or chronic infection can ... bile ducts, including the frequently fatal bile duct cancer - ... C. sinensis , published in BioMed Central,s open access journal ...
... researchers found a way of identifying ideal drug combinations ... occurring. The findings, published in Nature Chemical ... development of new drug combinations to combat severe diseases ... stroke and Alzheimer,s are worsened by inflammation, which is ...
... genetically engineered clotting factor that controlled hemophilia in an ... hemophilia and a broad range of other bleeding problems. ... Xa (FXa), a protein active in blood clotting, and ... bleeding in mouse models of hemophilia. "Our designed variant ...
Cached Biology News:Liver parasite lacks key genes for fatty acid synthesis: Genome sequencing of Clonorchis sinensis 2Manchester's 'first step' to perfect drug combinations 2Bioengineered protein shows preliminary promise as new therapy for hemophilia 2
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... imaging software for the microscopy market ... cameras, components and peripherals with powerful ... Its intuitive interface simplifies workflow and ... providing powerful features such as image ...
Biology Products: